Gene expression profile at single cell level of bone marrow mononuclear cells from MDS patients with secondary venetoclax-based therapy failure

Myelodysplastic syndromes (MDS) are incurable neoplasms that arise from early hematopoietic stem cells (HSCs). We used single cell RNA sequencing (scRNA-seq) to evaluate mechanisms of resistance to venetoclax-based therapies. Overall design: Bone marrow mononuclear cells were isolated by Fluorescence-activated cell sorting (FACS) and analyzed using scRNAseq.

骨髓增生异常综合征（Myelodysplastic syndromes, MDS）是一类起源于早期造血干细胞（hematopoietic stem cells, HSCs）的不可治愈性肿瘤性疾病。本研究采用单细胞RNA测序（single cell RNA sequencing, scRNA-seq）技术，评估基于维奈克拉（venetoclax）的治疗方案的耐药机制。总体实验设计：通过荧光激活细胞分选术（Fluorescence-activated cell sorting, FACS）分离骨髓单个核细胞，并利用scRNA-seq进行分析。